Epithelioid sarcoma
MONDO:0017387An aggressive malignant neoplasm of uncertain differentiation, characterized by the presence of epithelioid cells forming nodular patterns. The nodules often undergo central necrosis, resulting in a pseudogranulomatous growth pattern. It usually occurs in young adults. The most common sites of involvement are the extremities (distal-type epithelioid sarcoma), and less frequently the pelvis, perineum, and genital organs (proximal-type epithelioid sarcoma).
Also known as: ES, epithelioid cell sarcoma, epithelioid sarcoma
2836 clinical trials for this condition and its sub-types, 20 tagged with Epithelioid sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Epithelioid sarcoma
-
Adult epithelioid sarcoma 0 trials
-
Childhood epithelioid sarcoma 0 trials
-
Peripheral epithelioid sarcoma 0 trials
-
Proximal-type epithelioid sarcoma 0 trials
1 sub-type
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a simple test predict who will respond to this sarcoma drug?
Knowledge-focused CompletedThis study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC